Together, BluTest Laboratories LTD (“BluTest”) and the Tentamus Group (“Tentamus”) are excited to announce the acquisition of BluTest by Tentamus. Tentamus is thrilled to welcome BluTest as its newest member to the global network of laboratories, on the 28th of May 2021.
“BluTest is not only our first step into Scotland but immensely expands our expertise in the anti-microbials, biocidal, disinfectant, infection control and biofilm market, serving all of our key industries as a key R&D, NPD and TIC provider. Located in Glasgow, the state-of-the-art facility enables us to expand our global reach, especially in virology”, emphasizes Abgar Barseyten, CEO Tentamus Group. “It is an exceptional opportunity to grow the network and widen our joint presence well beyond what could be achieved independently”.
Chris Woodall, CEO and founder of BluTest adds: “it was our goal to win an international strategic partner who compliments our service offering. With Tentamus we found exactly that, which enables us to grow even faster now and support our customers’ needs and wants nationally and globally. Joining the worldwide laboratory network of Tentamus opens new opportunities for us and our customers alike. We are delighted and excited about the journey ahead.”
About BluTest Laboratories LTD
BluTest is a microbiology TIC/CRO provider focused on biocide (disinfectant) efficacy testing, new product development (pharmaceutical medical device biocide), disinfectant validation studies, virology and biofilm services. Located in Glasgow, BluTest supports national, European and global clients with close to 20 highly qualified professionals for an over a decade with expertise required now more than ever. Please find further information at http://www.blutest.com
Contact:
Chris Woodall, CEO BluTest
chris.woodall@blutest.com
Larissa Taylor, Country Manager Tentamus UK
larissa.taylor@fdas.org
+44 115 912 42 65